TD Asset Management Inc Purchases 22,906 Shares of Pharvaris N.V. (NASDAQ:PHVS)

TD Asset Management Inc increased its position in shares of Pharvaris N.V. (NASDAQ:PHVS - Free Report) by 41.5% in the first quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 78,122 shares of the company's stock after buying an additional 22,906 shares during the quarter. TD Asset Management Inc owned 0.15% of Pharvaris worth $1,227,000 as of its most recent SEC filing.

A number of other hedge funds have also modified their holdings of the company. JPMorgan Chase & Co. boosted its stake in shares of Pharvaris by 1,125.3% during the 4th quarter. JPMorgan Chase & Co. now owns 3,100 shares of the company's stock worth $59,000 after acquiring an additional 2,847 shares during the period. Cubist Systematic Strategies LLC bought a new position in shares of Pharvaris during the 4th quarter worth approximately $64,000. KLP Kapitalforvaltning AS bought a new position in shares of Pharvaris during the 4th quarter worth approximately $111,000. Point72 Asset Management L.P. bought a new position in shares of Pharvaris during the 4th quarter worth approximately $152,000. Finally, Legal & General Group Plc lifted its holdings in Pharvaris by 11.2% during the 4th quarter. Legal & General Group Plc now owns 9,855 shares of the company's stock worth $189,000 after purchasing an additional 994 shares during the last quarter.

Wall Street Analysts Forecast Growth

Several analysts recently weighed in on the company. Wedbush reissued an "outperform" rating and set a $27.00 price target on shares of Pharvaris in a report on Thursday, June 5th. Cantor Fitzgerald dropped their price target on Pharvaris from $28.00 to $25.00 and set an "overweight" rating for the company in a report on Wednesday, May 14th. Finally, Guggenheim initiated coverage on Pharvaris in a report on Wednesday, June 11th. They issued a "buy" rating and a $32.00 price objective for the company. Five equities research analysts have rated the stock with a buy rating, According to MarketBeat.com, Pharvaris presently has a consensus rating of "Buy" and a consensus price target of $36.20.

Pharvaris Trading Down 1.1%

PHVS traded down $0.24 on Tuesday, reaching $21.00. The stock had a trading volume of 117,893 shares, compared to its average volume of 212,697. The firm has a 50-day moving average of $18.84 and a 200-day moving average of $17.06. Pharvaris N.V. has a fifty-two week low of $11.51 and a fifty-two week high of $26.33. The company has a market capitalization of $1.10 billion, a price-to-earnings ratio of -6.98 and a beta of -2.81.

Pharvaris (NASDAQ:PHVS - Get Free Report) last released its quarterly earnings results on Tuesday, May 13th. The company reported ($0.89) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.80) by ($0.09). Sell-side analysts anticipate that Pharvaris N.V. will post -2.71 EPS for the current fiscal year.

Pharvaris Company Profile

Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, rapid exposure soft capsule for patients suffering from acute HAE attacks which is under Phase 2 clinical trial; and PHVS719, a prophylactic extended-release tablet for HAE patients which is under Phase 1 clinical trial.